BR112015011974A2 - derivados de azaquinazolina carboxamida - Google Patents

derivados de azaquinazolina carboxamida

Info

Publication number
BR112015011974A2
BR112015011974A2 BR112015011974A BR112015011974A BR112015011974A2 BR 112015011974 A2 BR112015011974 A2 BR 112015011974A2 BR 112015011974 A BR112015011974 A BR 112015011974A BR 112015011974 A BR112015011974 A BR 112015011974A BR 112015011974 A2 BR112015011974 A2 BR 112015011974A2
Authority
BR
Brazil
Prior art keywords
carboxamide derivatives
azaquinazoline
azaquinazoline carboxamide
derivatives
p70s6k
Prior art date
Application number
BR112015011974A
Other languages
English (en)
Other versions
BR112015011974A8 (pt
Inventor
Goutopoulos Andreas
R Huck Bayard
Neagu Constantin
Potnick Justin
Celeste Deselm Lizbeth
W Jr Cronin Mark
Boivin Roch
Lan Ruoxi
L Johnson Theresa
Chen Xiaoling
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112015011974A2 publication Critical patent/BR112015011974A2/pt
Publication of BR112015011974A8 publication Critical patent/BR112015011974A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "derivados de azaquinazolina carboxamida". a presente invenção refere-se a novos derivados de azaquinazolina carboxamida de fórmula (i) (i) em que w1, w2, w3, w4, r1, r2, r3 e m que foram definidos acima, são inibidores de p70s6k, e podem ser empregados, inter alia, para o tratamento de distúrbios hiperproliferativos.
BR112015011974A 2012-11-29 2013-11-27 derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica BR112015011974A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731075P 2012-11-29 2012-11-29
PCT/US2013/072141 WO2014085528A1 (en) 2012-11-29 2013-11-27 Azaquinazoline carboxamide derivatives

Publications (2)

Publication Number Publication Date
BR112015011974A2 true BR112015011974A2 (pt) 2017-07-11
BR112015011974A8 BR112015011974A8 (pt) 2019-10-08

Family

ID=49759613

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011974A BR112015011974A8 (pt) 2012-11-29 2013-11-27 derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica

Country Status (19)

Country Link
US (3) US9440968B2 (pt)
EP (1) EP2925747B1 (pt)
JP (1) JP6290917B2 (pt)
KR (1) KR20150090044A (pt)
CN (1) CN105793254B (pt)
AU (1) AU2013352261B2 (pt)
BR (1) BR112015011974A8 (pt)
CA (1) CA2887539C (pt)
CL (1) CL2015001187A1 (pt)
EA (2) EA033655B1 (pt)
ES (1) ES2821102T3 (pt)
IL (2) IL239054B (pt)
MX (1) MX2015006516A (pt)
NZ (1) NZ706418A (pt)
PE (1) PE20151782A1 (pt)
PH (2) PH12015500712A1 (pt)
SG (2) SG10201800741QA (pt)
UA (1) UA115154C2 (pt)
WO (1) WO2014085528A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6290917B2 (ja) * 2012-11-29 2018-03-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ アザキナゾリンカルボキサミド誘導体
EP3356348B1 (en) 2015-10-02 2021-05-05 Sentinel Oncology Limited 2-aminoquinazoline derivatives as p70s6 kinase inhibitors
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US20230002359A1 (en) 2019-11-01 2023-01-05 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
CR20240002A (es) 2021-06-24 2024-02-13 Syngenta Crop Protection Ag Derivados de 2-[3-[1 [(quinazolin-4-il)amino]etil]pirazin-2-il]tiazol-5-carbonitrilo y compuestos similares como plaguicidas
WO2023247360A1 (en) 2022-06-21 2023-12-28 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
CN117304182A (zh) * 2022-06-22 2023-12-29 上海海和药物研究开发股份有限公司 一类具有嘧啶并六元环结构的化合物、包含其的药物组合物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA287539A (en) * 1929-02-26 William Hallden Karl Severing apparatus
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
AU4718997A (en) 1996-11-27 1998-06-22 Pfizer Inc. Fused bicyclic pyrimidine derivatives
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
WO2004014873A1 (ja) * 2002-08-09 2004-02-19 Kyorin Pharmaceutical Co., Ltd. 4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩
AU2004230841A1 (en) 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
WO2005033086A1 (en) 2003-09-30 2005-04-14 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2541989C (en) 2003-10-24 2013-10-01 Exelixis, Inc. P70s6 kinase modulators and method of use
KR20060117329A (ko) 2003-11-21 2006-11-16 노파르티스 아게 단백질 키나제 저해제로서의 1ｈ-이미다조퀴놀린 유도체
TR200808208T1 (tr) 2003-12-09 2008-12-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bir immün tepkinin bastırılması veya proliferatif bir hastalığın tedavisi
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
EP1902032A1 (en) 2005-06-22 2008-03-26 Astex Therapeutics Limited Pharmaceutical compounds
KR101464384B1 (ko) 2005-11-22 2014-11-21 쿠도스 파마슈티칼스 리미티드 ｍＴＯＲ 억제제로서 피리도피리미딘, 피라조피리미딘 및피리미도피리미딘 유도체
MX2009010218A (es) 2007-03-23 2009-10-19 Hoffmann La Roche Derivados de aza-piridopirimidinona.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
CN101230045B (zh) * 2008-02-14 2013-04-10 沈阳药科大学 芳环并三嗪类衍生物及其应用
DK2396307T3 (en) * 2009-02-11 2015-01-12 Merck Patent Gmbh NOVEL AMINO-azaheterocyclic carboxamides
WO2011025938A2 (en) * 2009-08-28 2011-03-03 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CA2803387C (en) * 2010-07-29 2017-12-05 Bayard R. Huck Cyclic amine azaheterocyclic carboxamides
UA110113C2 (xx) * 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
JP5897590B2 (ja) * 2010-11-24 2016-03-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナゾリンカルボキサミドアゼチジン
US8791091B2 (en) 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
JP6290917B2 (ja) * 2012-11-29 2018-03-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ アザキナゾリンカルボキサミド誘導体

Also Published As

Publication number Publication date
IL239054B (en) 2021-04-29
PH12016502534A1 (en) 2017-11-20
KR20150090044A (ko) 2015-08-05
EA029144B1 (ru) 2018-02-28
EA201500573A1 (ru) 2016-02-29
UA115154C2 (uk) 2017-09-25
MX2015006516A (es) 2015-08-14
US20150259339A1 (en) 2015-09-17
PE20151782A1 (es) 2015-12-02
EA033655B1 (ru) 2019-11-13
EP2925747A1 (en) 2015-10-07
AU2013352261B2 (en) 2018-05-10
ES2821102T3 (es) 2021-04-23
PH12015500712B1 (en) 2015-05-18
IL256646B (en) 2020-03-31
CN105793254B (zh) 2020-10-23
SG11201502503RA (en) 2015-04-29
US9440968B2 (en) 2016-09-13
US10233160B2 (en) 2019-03-19
CL2015001187A1 (es) 2015-08-28
NZ706418A (en) 2019-09-27
JP6290917B2 (ja) 2018-03-07
US20180237402A1 (en) 2018-08-23
EA201792187A1 (ru) 2018-02-28
SG10201800741QA (en) 2018-03-28
IL239054A0 (en) 2015-07-30
CN105793254A (zh) 2016-07-20
PH12016502534B1 (en) 2017-11-20
WO2014085528A1 (en) 2014-06-05
CA2887539C (en) 2021-10-26
IL256646A (en) 2018-02-28
US9981925B2 (en) 2018-05-29
EP2925747B1 (en) 2020-06-24
CA2887539A1 (en) 2014-06-05
PH12015500712A1 (en) 2015-05-18
AU2013352261A1 (en) 2015-04-23
JP2016501229A (ja) 2016-01-18
US20160340323A1 (en) 2016-11-24
BR112015011974A8 (pt) 2019-10-08

Similar Documents

Publication Publication Date Title
BR112015011974A2 (pt) derivados de azaquinazolina carboxamida
EA201491936A1 (ru) Азотсодержащее гетероциклическое соединение
UA110338C2 (en) Chemical compounds
BR112014017021A8 (pt) inibidores de irak e usos dos mesmos
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
GEP20146197B (en) New compounds
UA111161C2 (uk) Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування
EA201201648A1 (ru) Стимуляторы sgc
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
BR112014028042A2 (pt) inibidores de nampt
CR20140494A (es) Inhibidores de dgat1 de eter ciclico de cabeza de puente
BR112014003693A2 (pt) amino quinazolinas como inibidores de quinase
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
MA32544B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
BR112014005581A2 (pt) compostos inibidores de enzima
PH12015501038A1 (en) Inhibitors of iap
PH12017500351A1 (en) N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
BR112013027395A2 (pt) inibidores de 17alfa-hidroxilase/c17,20-liase
BR112015008171A2 (pt) processos para a síntese de 2-amino-4,6-dimetoxibenzamida e de outros compostos de benzamida
EA201592167A1 (ru) Способ получения производных пирролидин-2-карбоновой кислоты
BR112013028945A2 (pt) novos compostos de hexahidropirroloimidazolona
EA201300408A1 (ru) Производные фенилхиназолина
TH163132B (th) อนุพันธ์เบนซิแลมีนที่เป็นตัวยับยั้งแคลลิครีนในพลาสมา
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors
MX2015006807A (es) Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements